Chiesi Farmaceutici S.p.a.
Clinical trials sponsored by Chiesi Farmaceutici S.p.a., explained in plain language.
-
New inhaler aims to tame uncontrolled asthma
Disease control TerminatedThis study tested an experimental inhaler (CHF6001) added to standard asthma medications in 517 adults with uncontrolled asthma. The goal was to see if it could reduce severe asthma attacks over a year. The trial was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New COPD combo therapy falls short in major trial
Disease control TerminatedThis study tested whether adding an experimental inhaler (CHF6001) to standard triple therapy could reduce flare-ups in people with severe COPD and chronic bronchitis. It included nearly 4,000 adults aged 40 and older who were current or former smokers. The trial was stopped earl…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New COPD inhaler combo studied to cut Flare-Ups
Disease control TerminatedThis study tested whether adding an experimental inhaler (CHF6001) to standard triple therapy could reduce flare-ups in people with COPD and chronic bronchitis. It involved about 4,700 adults aged 40 and older who were current or former smokers with moderate to severe COPD. The t…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 13, 2026 16:03 UTC